REG - Destiny Pharma PLC - Last Day of Dealings on AIM

Destiny PharmaAnnouncement

12/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240812:nRSL9547Za&default-theme=true

RNS Number : 9547Z  Destiny Pharma PLC  12 August 2024

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Last Day of Dealings on AIM

Brighton, United Kingdom - 12 August 2024 - Destiny Pharma plc (AIM: DEST),
a clinical stage biotechnology company focused on the development and
commercialisation of novel medicines to prevent and cure life-threatening
infections, reminds shareholders that the last day of trading in Destiny
Pharma's ordinary shares on AIM is today, 12 August 2024.

 

The cancellation of the admission of the Company's ordinary shares to trading
on AIM (the "Cancellation") was originally announced on 15 July 2024 and was
approved by shareholders at the general meeting held on 31 July 2024.

The Cancellation will become effective at 7:00 a.m. on 13 August 2024.
Following Cancellation, the Company will re-register as a private company
under the name Destiny Pharma Limited.

Matched Bargain Facility Arrangements

The Company's ordinary shares will be admitted to trading on the JP
Jenkins securities matching platform from 13 August 2024.

JP Jenkins provides a securities matching venue for unlisted or unquoted
assets in companies, enabling shareholders and prospective investors to buy
and sell shares on a matched bargain basis. JP Jenkins is a trading name of
InfinitX Limited and Appointed Representative of Prosper Capital LLP
(FRN453007).

Shareholders wishing to trade these securities can do so through their
stockbroker. Trades will be conducted at a level that JP Jenkins is able to
match a willing seller and a willing buyer. Trades can be conducted, and
limits can be accepted, during normal business hours. Shareholders or
potential investors can place limits via their existing UK regulated
stockbroker.

The indicative pricing for the ordinary Shares (ISIN: GB00BDHSP575), as well
as the transaction history, will be available on the JP Jenkins website
at (https://jpjenkins.com/company/destinypharma
(https://jpjenkins.com/company/destinypharma) ).

Following Cancellation, shareholders are encouraged to sign up to the
Company's email news alerts via the Destiny Pharma website to remain up to
date with the Company's developments.

Further details regarding the Cancellation and re-registration are set out in
the circular sent to shareholders dated 15 July 2024. A copy of the circular
is available on the Company's website www.destinypharma.com
(http://www.destinypharma.com)

Following Cancellation, Shore Capital will cease to act as nominated adviser
and corporate broker to the Company.

For further information, please contact:

 

Destiny Pharma plc
Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com

 

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

destinypharma@fticonsulting.com

 

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

 

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development pipeline includes
two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA
and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.

 

For further information on the company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86YTgzNTY4M2FkNmQyNzcyNmJlNWViN2U1MzU0ZjJmN2U6NjoxYWQ4OmYzMjJhZGVkMjlkZTUxYjRlYTI3M2QxNTNjYzkyYmEzZGU0ZGNlMWEzN2E2NjE3YzA5NGFkOTRkZmRjZGUyYjc6cDpG)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCXKLFBZVLLBBE